Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurocrine Bioscienc
(NQ:
NBIX
)
117.56
+1.12 (+0.96%)
Streaming Delayed Price
Updated: 12:06 PM EDT, Oct 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
November 14, 2022
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at...
Via
Benzinga
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
November 11, 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Via
MarketBeat
Looking Into Neurocrine Biosciences's Return On Capital Employed
November 09, 2022
According to Benzinga Pro, during Q3, Neurocrine Biosciences (NASDAQ:NBIX) earned $68.50 million, a 505.33% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $387.90...
Via
Benzinga
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
November 04, 2022
A mixed jobs report and heavy earnings swung stocks.
Via
Investor's Business Daily
Neurocrine Biosciences Buys UK-Based Hormone Therapy Player
August 30, 2022
Via
Benzinga
Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat
November 01, 2022
The company raised its guidance for Ingrezza sales in 2022.
Via
Investor's Business Daily
Neurocrine Biosciences: Q3 Earnings Insights
November 01, 2022
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance
August 05, 2022
Via
Benzinga
Earnings Scheduled For November 1, 2022
November 01, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.
Via
Benzinga
3 Top Biotech Stocks Defying the Bear Market
October 11, 2022
Bear market, shmear market. These biotech stocks are soaring despite the market downturn.
Via
The Motley Fool
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
4 Analysts Have This to Say About Neurocrine Biosciences
September 26, 2022
Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022
September 26, 2022
Upgrades
Via
Benzinga
Neurocrine Biosciences Shelves Key Drug; Will It Overshadow The Earnings Beat?
August 04, 2022
Neurocrine says the essential tremor drug didn't hit its goals in a key study.
Via
Investor's Business Daily
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
September 24, 2022
Eli Lilly leads medical stocks setting up and showing relative strength.
Via
Investor's Business Daily
S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms
September 17, 2022
Devon Energy leads this weekend's watch list of stocks in a tough market.
Via
Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Neurocrine Leads 5 Stocks To Watch In Sickly Market
September 03, 2022
Neurocrine Biosciences leads five medical stocks showing resilience.
Via
Investor's Business Daily
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
August 05, 2022
The Nasdaq and small caps rose while the S&P 500 is hitting resistance.
Via
Investor's Business Daily
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Dow Jones Giant Amgen Leads 5 Stocks To Watch Near Buy Points
July 23, 2022
Dow Jones giant Amgen headlines five stocks to watch setting near buy points or key support levels that may offer early entries.
Via
Investor's Business Daily
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
July 11, 2022
Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.
Via
Benzinga
Neurocrine Biosciences Earnings Perspective: Return On Capital Employed
May 19, 2022
According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60...
Via
Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
May 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Neurocrine Biosciences: Q1 Earnings Insights
May 04, 2022
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET
April 25, 2022
Neurocrine Biosciences (NASDAQ:NBIX) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
What 8 Analyst Ratings Have To Say About Neurocrine Biosciences
April 04, 2022
Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
March 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.